Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease

Experimental Neurology

Volumn 182, Issue 2, 2003, Pages 483-489

  Xie, Junxia ^a   Jiang, Hong ^a,b   Chen, Wenfang ^a,b   Qian, Zhong Ming ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Desferrioxamine; Dopamine release and content; Intranigral iron injection; Nigrostriatal dopaminergic neurons; Parkinson's disease

Indexed keywords

DEFEROXAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG INJECTION VOLUME; FEMALE; IRON KINETICS; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PUTAMEN; RAT; SUBSTANTIA NIGRA; TURNOVER TIME;

EID: 0042164632     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00123-7     Document Type: Article

References (44)

1. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2:2001;325-334.
2. Ben-Shachar D., Youdim M.B.H. Intranigral iron injection induces behavioral and biochemical "Parkinsonism" in rats. J. Neurochem. 57:1991;2133-2135.
3. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B.H. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1411-1444.
4. Berg D., Grote C., Rausch W.D., Maurer M., Wesemann W., Riederer P., Becker G. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound. Med. Biol. 25:1999;901-904.
5. Berg D., Gerlach M., Youdim M.B., Double K.L., Zecca L., Riederer P., Becker G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79:2001;225-236.
6. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306.
7. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. Bioessays. 24:2002;308-318.
8. Bonn D. Pumping iron in Parkinson's disease. Lancet. 347:1996;1614.
9. Borisenko G.G., Kagan V., Hsia C.J., Schor N.F. Interaction between 6-hydroxydopamine and transferrin "Let my iron go." Biochemistry. 39:2000;3392-3400.
10. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkin son's disease studies on medial forebrain bundle and striatal lesions . Neuroscience. 88:1999;617-628.
11. Dawson V.L., Dawson T.M. Free radicals and neuronal cell death. Cell Death Defferent. 3:1996;71-78.
12. Dawson T., Mandir A., Lee M. Animal models of PD pieces of the same puzzle? Neuron. 35:2002;219-222.
13. Double K.L., Gerlach M., Youdim M.B., Riederer P. Impaired iron homeostasis in Parkinson's disease. J. Neural. Transm. 60:2000;s37-s58.
14. Earl C.D., Reum T., Xie J.X., Sautter J., Kupsch A., Oertel W.H., Morgenstern R. Foetal nigral cell suspension grafts influenced dopamine release in the non-grafted side in the 6-OHDA rat model of Parkinson's disease in vivo voltammetrice data . Exp. Brain. Res. 109:1996;179-184.
15. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
16. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology. 45:1995;1138-1143.
17. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson's disease an in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy . Brain. 122:1999;667-673.
18. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease an X-ray microanalysis . J Neurochem. 56:1991;446-451.
19. Jellinger K.A. The role of iron in neurodegeneration. Drugs Aging. 14:1999;115-140.
20. Jiang H., Chen W.F., Xie J.X. Relationship between dopamine and iron contents in the brain of Parkinsonian rats. Acta Physiologica Sinica. 53:2001;334-338.
21. Kienzl E., Jellinger K., Stachelberger H., Linert W. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? Life Sci. 65:1999;1973-1976.
22. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:1998;259-277.
23. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system . J. Neurosci. 20:2000;4686-4700.
24. Kirik D., Winkler C., Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 21:2001;2889-2896.
25. Kress G.J., Dineley K.E., Reynolds I.J. The relationship between intracellular free iron and cell injury in cultured neurons, astrocytes, and oligodendrocytes. J. Neurosci. 22:2002;5848-5855.
26. Monteiro H.P., Winterbourn C.C. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38:1989;4177-4182.
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Co-ordinates. 2nd ed: 1986;Academic Press, London, UK.
28. Ponting C.P. Domain homologues of dopamine beta-hydroxylase and ferric reductase roles for iron metabolism in neurodegenerative disorders? Hum. Mol. Genet. 10:2001;1853-1858.
29. Qian Z.M., Wang Q. Expression of iron transport proteins and excessive iron accumulation of iron in the brain in neurodegenerative disorders. Brain Res. Rev. 27:1998;257-267.
30. Qian Z.M., Pu Y.M., Wang Q. Brain iron and neurological disorders. Chin. J. Med. 110:1997;455-458.
31. Qian Z.M., Shen X. Brain iron transport and neurodegeneration. Trend. Mol. Med. 7:2001;103-108.
32. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
33. Riederer P., Dirr A., Goetz M., Sofic E., Jellinger K., Youdim M.B. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol. 32:1992;S101-104.
34. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural. Transm. 108:2001;1263-1282.
35. Shoham S., Youdim M.B. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell. Mol. Biol. 46:2000;743-760.
36. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm. 74:1988;199-205.
37. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56:1991;978-982.
38. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61:1993;1191-1206.
39. Xie J.X., Tang M. Effects of electric stimulation of the dopaminergic nerve fiber or nerve terminal or striatal dopamine release in the rat. Chin. J. Neurosci. 15:1999;20-26.
40. Xie J.X., Zhou Y., Jiang H. Monitoring dopamine release by fast cyclic voltammetry an in vivo study . Chin. Appl. Physiol. 16:2000;109-113.
41. Youdim M.B., Ben-Shachar D., Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeration? Acta Neuro. Scand. 126:1989;47-54.
42. Youdim M.B., Ben-Shachar D., Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8:1993;1-12.
43. Zhou Y., Zhao Z.Q., Xie J.X. Effects of isatin on rotational behavior and DA levels in caudate putamen in Parkinsonian rats. Brain Res. 917:2001;127-132.
44. Zigmond M.J., Stricker E.M. Animal models of parkinsonism using selective neurotoxins clinical and basic implications . Int. Rev. Neurobiol. 31:1989;1-79.